This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-85. 10.1158/1078-0432.CCR-04-2421RouzierRPerouCMSymmansWFIbrahimNCristofanilliMAndersonKet alBreast cancer molecular subtypes respond differently to preoperative chemotherapyClin Cancer Res2005115678–8510.1158/1078-0432.CCR-04-2421Open DOISearch in Google Scholar
Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol 2014; 5: 412-24. 10.5306/wjco.v5.i3.412YersalOBarutcaSBiological subtypes of breast cancer: prognostic and therapeutic implicationsWorld J Clin Oncol20145412–2410.5306/wjco.v5.i3.412Open DOISearch in Google Scholar
Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 2001; 30: 96-102. PMID: 11773300WolmarkNWangJMamounasEBryantJFisherBPreoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18J Natl Cancer Inst Monogr20013096–1021177330010.1093/oxfordjournals.jncimonographs.a003469Search in Google Scholar
Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methrotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009; 27: 2474-81. 10.1200/JCO.2008.19.2567GianniLBaselgaJEiermannWPortaVGSemiglazovVLluchAet alPhase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methrotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast CancerJ Clin Oncol2009272474–8110.1200/JCO.2008.19.2567Open DOISearch in Google Scholar
Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011; 47: 2084-90. 10.1016/j.ejca.2011.06.014KongXMoranMSZhangNHafftyBYangQMeta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patientsEur J Cancer2011472084–9010.1016/j.ejca.2011.06.014Open DOISearch in Google Scholar
Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responsers: triple-negative and HER2+ subtypes. Ann Surg Oncol 2018; 25: 2241-8. 10.1245/s10434-018-6531-5MurphyBLDayCNHoskinTLHabermannEBBougheyJCNeoadjuvant chemotherapy use in breast cancer is greatest in excellent responsers: triple-negative and HER2+ subtypesAnn Surg Oncol2018252241–810.1245/s10434-018-6531-5Open DOISearch in Google Scholar
Boughey J, McCall L, Ballman K, Mittendorf EA, Ahrendt GM, Wilke LG, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer. Ann Surg 2014; 260: 608-16. 10.1097/SLA.0000000000000924BougheyJMcCallLBallmanKMittendorfEAAhrendtGMWilkeLGet alTumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancerAnn Surg2014260608–1610.1097/SLA.0000000000000924Open DOISearch in Google Scholar
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-804. 10.1200/JCO.2011.38.8595von MinckwitzGUntchMBlohmerJUCostaSDEidtmannHFaschingPAet alDefinition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypesJ Clin Oncol2012301796–80410.1200/JCO.2011.38.8595Open DOISearch in Google Scholar
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-72. 10.1016/S0140-6736(13)62422-8CortazarPZhangLUntchMMehtaKCostantinoJPWolmarkNet alPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384164–7210.1016/S0140-6736(13)62422-8Open DOISearch in Google Scholar
Boughey JC, Ballman KV, McCall LM, Mittendorf EA, Symmans WF, Julian TB, et al. Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance). Ann Surg 2017; 266: 667-76. 10.1097/SLA.0000000000002373BougheyJCBallmanKVMcCallLMMittendorfEASymmansWFJulianTBet alTumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance)Ann Surg2017266667–7610.1097/SLA.0000000000002373Open DOISearch in Google Scholar
Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol 2015; 22: 1416-24. 10.1245/s10434-015-4403-9DialaniVChadashviliTSlanetzPJRole of imaging in neoadjuvant therapy for breast cancerAnn Surg Oncol2015221416–2410.1245/s10434-015-4403-9Open DOISearch in Google Scholar
Straver ME, Loo CE, Rutgers EJ, Oldenburg HS, Wesseling J, Vrancken Peeters MJ, et al. MRI model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg 2010; 251: 701-7. 10.1097/SLA.0b013e3181c5dda3StraverMELooCERutgersEJOldenburgHSWesselingJVranckenPeeters MJet alMRI model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapyAnn Surg2010251701–710.1097/SLA.0b013e3181c5dda3Open DOISearch in Google Scholar
De los Santos J, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer 2013; 119: 1776-83. 10.1002/cncr.27995De losSantos JCantorAAmosKDForeroAGolshanMHortonJKet alMagnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancerTranslational Breast Cancer Research Consortium trial 017. Cancer20131191776–8310.1002/cncr.27995Open DOISearch in Google Scholar
McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 2011; 18: 3149-54. 10.1245/s10434-011-1912-zMcGuireKPToro-BurgueteJDangHYoungJSoranAZuleyMet alMRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?Ann Surg Oncol2011183149–5410.1245/s10434-011-1912-zOpen DOISearch in Google Scholar
Fukuda T, Horii R, Gomi N, Miyagi Y, Takahashi S, Ito Y, et al. Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype. Springerplus 2016; 5: 152. 10.1186/s40064-016-1800-xFukudaTHoriiRGomiNMiyagiYTakahashiSItoYet alAccuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtypeSpringerplus2016515210.1186/s40064-016-1800-xOpen DOISearch in Google Scholar
Bouzón A, Acea B, Soler R, Iglesias Á, Santiago P, Mosquera J, et al. Diagnostic accuracy of MRI to evaluate tomour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients Radiol Oncol 2016; 50: 73-9. 10.1515/raon-2016-0007BouzónAAceaBSolerRIglesiasÁSantiagoPMosqueraJet alDiagnostic accuracy of MRI to evaluate tomour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patientsRadiol Oncol20165073–910.1515/raon-2016-0007Open DOISearch in Google Scholar
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Ann Oncol 2013; 24: 2206-23. 10.1093/annonc/mdt303GoldhirschAWinerEPCoatesASGelberRDPiccart-GebhartMThürlimannBet alPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Ann Oncol2013242206–2310.1093/annonc/mdt303Open DOISearch in Google Scholar
Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol 2003; 181: 1275-82. 10.2214/ajr.181.5.1811275RosenELBlackwellKLBakerJASooMSBentleyRCYuDet alAccuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapyAm J Roentgenol20031811275–8210.2214/ajr.181.5.1811275Open DOISearch in Google Scholar
Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am J Roentgenol 2005; 184: 868-77. 10.2214/ajr.184.3.01840868YehESlanetzPKopansDBRaffertyEGeorgian-SmithDMoyLet alProspective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancerAm J Roentgenol2005184868–7710.2214/ajr.184.3.01840868Open DOISearch in Google Scholar
Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol 2011; 18: 3160-3. 10.1245/s10434-011-1919-5CroshawRShapiro-WrightHSvenssonEErbKJulianTAccuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patientsAnn Surg Oncol2011183160–310.1245/s10434-011-1919-5Open DOISearch in Google Scholar
Orel S. Who should have breast magnetic resonance imaging evaluation? J Clin Oncol 2008; 26: 703-11. 10.1200/JCO.2007.14.3594OrelSWho should have breast magnetic resonance imaging evaluation?J Clin Oncol200826703–1110.1200/JCO.2007.14.3594Open DOISearch in Google Scholar
Eom HJ, Cha JH, Choi WJ, Chae EY, Shin HJ, Kim HH. Predictive clinicopathologic and dynamic contrast-enhanced MRI findings for tumor response to neoadjuvant chemotherapy in triple-negative breast cancer. Am J Roentgenol 2017; 208: 225-30. 10.2214/AJR.16.17125EomHJChaJHChoiWJChaeEYShinHJKimHHPredictive clinicopathologic and dynamic contrast-enhanced MRI findings for tumor response to neoadjuvant chemotherapy in triple-negative breast cancerAm J Roentgenol2017208225–3010.2214/AJR.16.17125Open DOISearch in Google Scholar
Wang J, Buchholz TA, Middleton L, Allred DC, Tucker SL, Kuerer HM, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 2002; 94: 3107-14. 10.1002/cncr.10585WangJBuchholzTAMiddletonLAllredDCTuckerSLKuererHMet alAssessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast cancerCancer2002943107–1410.1002/cncr.10585Open DOISearch in Google Scholar
Goorts B, van Nijnatten TJ, de Munck L, Moossdorff M, Heuts EM, de Boer M, et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2017; 163: 83-91. 10.1007/s10549-017-4155-2GoortsBvan NijnattenTJde MunckLMoossdorffMHeutsEMde BoerMet alClinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patientsBreast Cancer Res Treat201716383–9110.1007/s10549-017-4155-2Open DOISearch in Google Scholar
Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, et al. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol 2009; 16: 1619-28. 10.1245/s10434-009-0441-5BahriSChenJHMehtaRSCarpenterPMNieKKwonSYet alResidual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumabAnn Surg Oncol2009161619–2810.1245/s10434-009-0441-5Open DOISearch in Google Scholar
Ko ES, Han BK, Kim RB, Ko EY, Shin JH, Hahn SY, et al. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Ann Surg Oncol 2013; 20: 2562-8. 10.1245/s10434-013-2925-6KoESHanBKKimRBKoEYShinJHHahnSYet alAnalysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancerAnn Surg Oncol2013202562–810.1245/s10434-013-2925-6Open DOISearch in Google Scholar
Moon H-G, Han W, Ahn SK, Cho N, Moon WK, Im SA, et al. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy. Ann Surg 2013; 257: 133-7. doi:10.1097/SLA.0b013e3182686bd9MoonH-GHanWAhnSKChoNMoonWKImSAet alBreast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapyAnn Surg2013257133–710.1097/SLA.0b013e3182686bd9Open DOISearch in Google Scholar
Patel BK, Hilal T, Covington M, Zhang N, Kosiorek HE, Lobbes M, et al. Contrast-enhanced spectral mammography is comparable to MRI in the assessement of residual breast cancer following neoadjuvant systemic therapy. Ann Surg Oncol 2018; 25: 1350-6. 10.1245/s10434-018-6413-xPatelBKHilalTCovingtonMZhangNKosiorekHELobbesMet alContrast-enhanced spectral mammography is comparable to MRI in the assessement of residual breast cancer following neoadjuvant systemic therapyAnn Surg Oncol2018251350–610.1245/s10434-018-6413-xOpen DOISearch in Google Scholar
Rauch GM, Kuerer HM, Adrada B, Santiago L, Moseley T, Candelaria RP, et al. Biopsy feasibility trial for breast cancer pathologic complete response detection after neoadjuvant chemotherapy: imaging assessment and correlation endpoints. Ann Surg Oncol 2018; 25: 1953-60. doi:10.1245/s10434-018-6481-yRauchGMKuererHMAdradaBSantiagoLMoseleyTCandelariaRPet alBiopsy feasibility trial for breast cancer pathologic complete response detection after neoadjuvant chemotherapy: imaging assessment and correlation endpointsAnn Surg Oncol2018251953–6010.1245/s10434-018-6481-yOpen DOISearch in Google Scholar
Heldahl MG, Lundgren S, Jensen LR, Gribbestad IS, Bathen TF. Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T? J Magn Reson Imaging 2011; 34: 547-56. 10.1002/jmri.22642HeldahlMGLundgrenSJensenLRGribbestadISBathenTFMonitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T?J Magn Reson Imaging201134547–5610.1002/jmri.22642Open DOISearch in Google Scholar
